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Infectious diseases pose an increasing risk to health, especially in developing countries.
Vaccines are available to either cure or prevent many of these diseases. However,
there are certain limitations related to these vaccines, mainly the costs, which make
these vaccines mostly unaffordable for people in resource poor countries. These costs
are mainly related to production and purification of the products manufactured from
fermenter-based systems. Plastid biotechnology has become an attractive platform to
produce biopharmaceuticals in large amounts and cost-effectively. This is mainly due to
high copy number of plastids DNA in mature chloroplasts, a characteristic particularly
important for vaccine production in large amounts. An additional advantage lies in the
maternal inheritance of plastids in most plant species, which addresses the regulatory
concerns related to transgenic plants. These and many other aspects of plastids will
be discussed in the present review, especially those that particularly make these green
biofactories an attractive platform for vaccine production. A summary of recent vaccine
antigens against different human diseases expressed in plastids will also be presented.
Keywords: molecular farming, biopharmaceuticals, plant-based vaccines, plastids, infectious diseases,
developing countries, cost-effective vaccines
INTRODUCTION
Increase in the rate of infectious diseases is an escalating problem in both developed and developing
world. There are number of factors that play role in the incidence rate of infectious diseases. Among
these, main factors are global warming, lack of healthcare facilities, and costly preventive measures
or treatments. With increase in global warming, threat of infectious diseases is also rising. Data
from last 10 years show increase in the incidence of diseases and projections also predict more rise
in future (Altizer et al., 2013). In developed countries, enhanced rate of infectious diseases may
possibly be prevented by the availability of good healthcare facilities, cleaner resources and clean
environment. However, in developing countries, where 2.2 billion people lived on less than US $2 a
day in 2011 (World Bank, 2015), spread of infectious agents could be faster due to the reason that a
large population is not able to afford costs related to treatments of these diseases. In addition, poor
sanitation, malnutrition, use of unclean water and lack of precautionary measures at government
levels are additional major contributors to the increase in the risks of infectious diseases.
Considering above mentioned factors, there are number of levels at which disease spread could
be controlled. Two major levels include prevention and cure. Many diseases can be stopped more
effectively by taking preventive measures. However, for eradicating existing infections and to
control massive outbreaks of some infectious agents, cure is preferable. Keeping in view the scenario
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of developing countries, it is particularly important that these
preventive/treatment strategies should be affordable and cost-
effective. Use of vaccines can be an effective strategy that can
be either used as prophylactic (before the onset of disease) or
therapeutic (after the onset of disease). There are number of
platforms that are used for antigen-based vaccine production,
mainly mammalian cell culture based and fermentation-based
systems. However, many concerns are related to the vaccines that
are in market. Most important of these are cost, stability, safety,
and efficacy. Hence, alternate strategies needs to be opted to cover
the shortcomings of vaccines in use.
WHY CHLOROPLASTS?
There are various advantages of plant-based expression systems
that are generally related to plants and some relevant to
chloroplast-based expression only. In general, in relation to cost,
a major advantage is at production level, i.e., the up scaling of
plants to asmuch area as needed. If land is available, large number
of plants can be grown by using inexpensive resources. This is the
major level where cost is reduced in comparison to fermenters or
bioreactors where establishing and running of a total new setup
for up scaling is very costly. There are certain other advantages
that are particularly related to chloroplast-based expression of
vaccine antigens. Chloroplasts are organelles of plants present
in leaves and other green parts that carry out photosynthesis.
In recent biotechnological innovative era, chloroplasts have been
explored for the expression of foreign proteins, industrially
and pharmaceutically important compounds such as antibodies,
growth factors, enzymes, hormones, cytokines, and antigens
(Daniell et al., 2009; Lössl andWaheed, 2011). Previously, various
aspects of plant/chloroplast-based pharmaceutical compounds
have been extensively reviewed (Bock, 2014; Rybicki, 2014;
Abiri et al., 2015; Chan and Daniell, 2015; Fahad et al., 2015;
Salazar-González et al., 2015). Here we give an outline of
chloroplast transformation and certain characteristics of plastids
that are particularly important for the production of antigen-
based vaccines against human diseases at low costs. We will
review different aspects of chloroplasts for vaccine production
particularly relevant to cost, stability, safety, and efficacy.
PLASTID TRANSFORMATION
There are mainly two methods that are used for plastid
genome transformation: polyethylene glycol (PEG)-mediated
transformation and gene gun-mediated transformation. First
method is inexpensive and involves the isolation of protoplasts
that are later transformed in the presence of PEG. However, the
protoplast isolation is tricky and the protocols for protoplast
isolation and regeneration are not optimized for many edible
plant species. Transformation via particle delivery system (PDS)
is expensive, both in the expenses of biolistic gun (although
it is one time cost) and gold particles which are mostly
used for the delivery of foreign DNA into plastomes. Despite,
biolistic delivery is the most widely used method for chloroplast
transformation and protocols are very well established (Verma
et al., 2008; Abdel-Ghany et al., 2015). Different strategies have
been adopted over time to enhance the foreign protein expression
in chloroplasts attaining a very high amount of 72% of total
leaf protein (TLP) from tobacco leaves (Ruhlman et al., 2010).
These strategies include use of 5′ and 3′ untranslated regions or
regulatory elements, use of active promoter, N-terminal fusion of
a stabilizing peptide sequence and insertion site. Although there
are very few reports showing very high expression of proteins
in plastids, the expression levels in most studies of plastid
transformation cross minimum level required for a feasible large
scale commercial production, i.e., 1% of total soluble protein
(TSP) or 50µg/g fresh leaf tissue (Rybicki, 2009, 2010).
Integration of expression cassette in plastid genome takes
place via homologous recombination. Flanking sequences used
for insertion on right and left sides are amplified from the
species which is to be transformed and an expression cassette
is constructed through various cloning steps (Verma et al.,
2008; Bock, 2015). Choosing the insertion site for integration
of expression cassette within plastomes is one of the important
parameters for enhanced expression of transgenes. Different
insertion sites can lead to different levels of expression. Two
important parameters that should be kept inmindwhile choosing
the insertion sites are their location in actively transcribed
region and within the inverted repeat region of plastid genome
(Verma et al., 2008). Insertion site can also have some negative
effects on plants. Hence, to ensure safety of plant and enhanced
expression of a vaccine antigen in plastomes, care should be
taken in choosing the insertion site. Different insertion sites
along with respective expression levels are shown in Figure 1.
Since the flanking sequences are amplified from the plastome
of the target species, a resulting species-specific vector is likely
to express more in specific species for which it is designed.
It is known that certain level of sequence homology exists
between chloroplast genomes of different plant species (Bisaro
and Siegel, 1980). On this basis, concept of universal vector was
presented and it was proposed that a universal vector, having
flanking sequences that are conserved in most plant species, can
be constructed and utilized for transforming the plastomes of
many related plant species (Verma and Daniell, 2007). However,
using a universal vector may result in low expression. Hence
to achieve high expression, a species-specific vector should be
the choice. Nevertheless, it may be a technical challenge to
develop species-specific vector for each particular species to be
transformed because of lack of chloroplast genome sequence.
A typical expression cassette of a transformation vector that is
inserted in plastomes is shown in Figure 1. In this figure different
components of expression cassette along with their respective
yields of foreign proteins are also given. Data is given for those
reports where the expression level is up to 10% or above of
total soluble protein (TSP) or total leaf protein (TLP). Figure
shows that highest expression for a vaccine antigen, which is
72% of TLP (Ruhlman et al., 2010), was achieved by using
insertion sites trnI and trnA under the control of psbA promoter
with 5′ regulatory elements from psbA gene. Most reports in
the figure showing high expression of transgenes in plastids
use this cassette containing trnI and trnA as insertion sites,
promoter, 5′ regulatory elements and terminator from psbA
gene. Hence it can be concluded that this expression cassette
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FIGURE 1 | Diagrammatic presentation of constituents of expression cassette along with their respective expression levels for vaccine antigens.
Combinations of similar insertion sites, promoters, regulatory elements and terminators are shown in one color. SM, selection marker; RE, regulatory elements; UTR,
untranslated region; psbA, psbA gene; TpsbA, Terminator of psbA gene; rrn16, rrn 16 gene; T7g10, leader sequence of gene 10 of the lambda phage T7; rbcL, rbcL
gene; TrbcL, Terminator of rbcL gene; TrrnB, Escherichia coli rrnB terminator; TSP, total soluble protein; TLP, total leaf protein.
can serve as standard for attaining a high level expression in
chloroplasts.
After transformation, several rounds of selection and
regeneration are required on selection medium containing
appropriate antibiotic to regenerate the homoplasmic
transplastomic plants (Verma et al., 2008; Ahmad and Mukhtar,
2013). Homoplasmy refers to a state of plant when all chloroplasts
are transformed and no wild type untransformed copy of plastid
genome is left. However, to achieve homoplasmy, 1–2 extra
regeneration cycles on selection medium are necessary. In
comparison to mature leaves, very young leaves with immature
chloroplasts have low plastome copy number. If these leaves
are used for transformation, homoplasmy can be more quickly
attained during regeneration phase. Normally, revised medium
for organogenesis of plants (RMOP) is used, supplemented with
appropriate concentration of hormones to promote callogenesis
and shooting. For selection, antibiotic is added in the medium.
Only those plants regenerate on selection medium which contain
antibiotic resistant gene inside, i.e., transformed. Complete
transplastomic plants are regenerated under aseptic controlled
conditions and acclimatized to green house for further growth.
STABLE GENETIC RESOURCE
Once a complete transplastomic plant is regenerated via tissue
culture, seeds are collected for growing next generation. These
seeds can now serve as a stable genetic resource, an important
outcome of stable genetic transformation. The costs involved
in developing such resource are only one time, whether the
developmental experimental procedures are carried out in
academic research laboratories or at industrial scale. Currently,
most of the research work regarding developing initial platforms
and experimentations to develop techniques for enhancing the
expression levels of foreign proteins in plants is carried out
in academic research labs. Stable genetic resource in the form
of seeds can be preserved and grown at any place where the
vaccine production is required, exploiting a significant advantage
of plants, i.e., “grown at site.” This aspect has potential to
circumvent the costs related to transportations and cooling chain
in those cases when vaccines are produced elsewhere and need to
be transported to the target areas. Hence, it will ultimately reduce
the cost of final product in the market.
POLYPLOIDY AND VERY HIGH
EXPRESSION OF FOREIGN PROTEINS
An average tobacco leaf contains almost 100 chloroplasts per cell
and in each chloroplast there are approximately 100 chloroplast
genomes. In total, this makes 10,000 chloroplast genomes in
one cell (Maliga, 2002; Koop et al., 2007). Theoretically, if all
chloroplasts are transformed in each and every cell of every leaf
in a plant, this makes very high expression of a foreign protein
possible. In reality, a very high expression has been achieved,
reaching up to 72% of total leaf protein (TSP) and 70% of total
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soluble protein (TSP), reported by Ruhlman et al. (2010) and
Oey et al. (2009), respectively. For vaccine production at a cost-
effective rate, this very high expression can play a key role. Higher
the expression lesser will be the cost of final product because
more product will be produced from less resources. The potential
oral delivery of plant-based vaccines, which if possible in reality,
will also greatly reduce the costs due to elimination of costly
downstream processing. However, this does not seem to be a
reality at the present stage due to number of limitations (for
detailed discussion on this topic see Rybicki, 2009). In contrast,
if the purification of protein has to be done then cost reduction
is relevant only at production level, which is estimated to be
about 31% (Rybicki, 2009). In such case, using the chloroplast-
based expression and homoplasmy in which all plastomes are in
transformed state, can lead to very high expression. This feature
is expected to further reduce costs at production level because
more protein will be produced per kilogram weight of plant.
However, this also depends upon a number of other factors such
as use of plants with wide leaves and having high biomass. In
contrast to this characteristic of plastids, nuclear transformation,
where mostly 1–2 copies of transgenes are mostly inserted in the
nuclear genome, results in low yield (an average of 0.01–0.4% of
TSP; Daniell et al., 2001a). Thus, for vaccine production, a high
protein yielding platform such as chloroplasts needs to be opted.
Various antigen-based vaccine candidates have been expressed in
chloroplasts against number of human diseases. A detailed list
has been previously published by our group (Lössl and Waheed,
2011). Reports published onwards are summarized in Table 1.
ABSENCE OF EPIGENETIC EFFECTS
Plastids are double membrane organelles that originated from
prokaryotic symbionts and largely retained their characteristics
of prokaryotes. Presence of double membrane enables the
compartmentalized production of foreign proteins, thus
retaining the proteins inside. Due to this reason, there are
less chances of affecting the plant physiology by interfering
with cellular metabolic pathways of plants. Related to their
prokaryotic nature, an important fact is the absence of gene
silencing and other epigenetic effects in plastids. Till date,
there is no report of these effects taking place in plastids. This
characteristic of the green organelles ensures the stable and
continued expression of transgenes in chloroplasts. In contrast,
nuclear genome is susceptible to epigenetic effects which affect
the yield of foreign proteins.
EXPRESSION OF MULTIGENES AS SINGLE
OPERON
Vaccines are often accompanied with adjuvants that boost the
effect of a given antigen (Guy, 2007). Both chemical-based and
biological adjuvants can be used for this purpose. Escherichia
coli heat-labile enterotoxin subunit B (LTB) and cholera toxin
subunit B (CTB) are two biological adjuvants that can be given
with vaccine antigens to enhance their immunogenicity. Here,
another advantage of plastids can play a role for production of
vaccines coupled with biological adjuvants. Due to prokaryotic
nature of plastids, multiple genes can be stacked as a single
operon and co-expressed (Lössl and Waheed, 2011). Two or
more genetic sequences can be stacked one by one and expressed
under a single promoter. Utilizing this characteristic, coupled
expression of a biological adjuvant with an antigen in chloroplasts
can be achieved. In this way, costs related to separate production
of adjuvants can be eliminated. In addition, direct coupling
is believed to enhance the immunogenicity of antigens more
than their separate administration (Guy, 2007; Sánchez and
Holmgren, 2008) and it has been found that due to coupling
of antigen with CTB, much strong response is achieved upon
oral administration (Guo et al., 2012). This characteristic of
plastids to express many coding sequences as single operon can
also be utilized to develop bivalent to multivalent vaccines, in
which two or more vaccine antigens against different diseases
can be co-expressed. Development of multivalent vaccines, used
to cure multiple infections with one vaccine formulation can
be particularly important in case of patients with acquired
immunodeficiency syndrome (AIDS) where multiple diseases
may need to be cured at one time. This advantage of plastids
is also applicable for those vaccines that need more than one
epitope for their function.
Another advantage of using biological adjuvants and their
direct coupling is potential safety and efficacy. Use of biological
adjuvants will help to eliminate toxic chemical adjuvants
such as aluminum hydroxide and aluminum phosphate which
commonly cause many adverse side effects such as local irritation
and carcinogenesis (Gupta and Siber, 1995; Sun et al., 2006).
Thus, use of biological adjuvants addresses the safety concern.
Additionally, direct coupling of adjuvants is advantageous in
terms of efficacy of antigen. Direct coupling not only can enhance
the immunogenicity of an antigen but also the adjuvanticity is
presumed to be more pronounced in an adjuvant-antigen couple.
Furthermore, if an adjuvant such as LTB is directly linked with
an antigen, it can facilitate the entry of antigen through gut
mucosa, bind to GM1-ganglioside receptors and aid in eliciting
the protective immunity (Granell et al., 2010; Salyaev et al., 2010).
SAFETY OF
PLANTS/CHLOROPLAST-DERIVED
VACCINES
Safety concerns arise at two levels related to plant-based vaccines:
the environment safety and safety of final product for patients.
To successfully launch these vaccines into market, both these
concerns are essential to address in order to get the approval from
competent authorities.
MATERNAL INHERITANCE OF PLASTID
GENOME
A major concern related to regulatory approval of plant-
based pharmaceuticals is environment safety. Environment can
be potentially contaminated by unwanted flow of transgenes,
especially antibiotic resistant marker genes, to the wild species
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TABLE 1 | Different vaccine antigens against human diseases expressed via plastid genome since 2011.
Vaccine Antigen (Disease) Expression
system
Maximum expression level Immunological investigation References
VIRAL ANTIGENS
Dengue epitope region of E protein of
DENV domain I and II (Dengue fever)
Lettuce Not reported Cross reaction of antibodies from
the sera of dengue patients
Maldaner et al., 2013
Dengue-3 serotype capsid complete
premembrane (prM) and truncated
envelope (E) protein prM/E (Dengue
fever)
Lettuce Not reported Not tested Kanagaraj et al., 2011
Mutated human papillomavirus
(HPV)-16 oncoprotein E7 (cervical
cancer)
Chlamydomonas
reinhardtii
Not reported Vaccination in mice with algae
extracts showed high level of
E7-specific antibodies but low
activation of E7-specific CD8+
cells
Vlasák et al., 2013
Mutated, attenuated E7 oncoprotein
(E7GGG), alone or as a fusion with
affinity tags (His6 or FLAG) (cervical
cancer)
Chlamydomonas
reinhardtii
0.12% of total soluble protein (TSP) Induction of specific anti-E7 IgGs
and E7-specific T-cell proliferation
detected in C57BL/6 mice
vaccinated with total
Chlamydomonas extract and with
affinity-purified protein
Demurtas et al., 2013
E7 translationally fused with
β-glucuronidase
Tobacco GUS-E7 showed expression between
30 and 40 times higher than
previously reported for unfused E7
(0.1% of TSP)
Not tested Morgenfeld et al., 2014
Modified HPV-16 L1 gene fused with
glutathione-S-transferase (GST)
GST-L1_2xCysM (cervical cancer)
Tobacco Not detected Not tested Hassan et al., 2014
Synthetic gene encoding a C4V3
recombinant protein (HIV)
Tobacco ∼25µg/g of fresh weight Plant-derived C4V3 has elicited
both systemic and mucosal
antibody responses in BALB/c
mice, as well as CD4+ T cell
proliferation responses
Rubio-Infante et al., 2012
Multiepitopic protein (Multi-HIV)
carrying several neutralizing epitopes
from both gp120 and gp41 (AIDS)
Tobacco Protein accumulation levels up to
16µg/g of fresh tobacco biomass
Multi-HIV protein was able to elicit
humoral responses in mice when
orally administered
Rosales-Mendoza et al.,
2014
HIV-1 capsid protein p24 alone and in
fusion with the negative regulatory
protein Nef (p24-Nef) (AIDS)
Tobacco P24 up to ∼4% and p24-Nef up to
∼40% of TSP
Subcutaneous immunization with
purified chloroplast-derived p24
elicited a strong antigen-specific
serum IgG response. Oral
administration of a partially purified
chloroplast-derived p24-Nef fusion
protein, used as a booster after
subcutaneous injection with either
p24 or Nef, also elicited strong
antigen-specific serum IgG
responses
McCabe et al., 2008;
Zhou et al., 2008;
Gonzalez-Rabade et al.,
2011
Rotavirus VP6 gene (gastroenteritis) Tobacco >15% of total leaf protein (TLP) Not tested Inka Borchers et al., 2012
BACTERIAL ANTIGENS
Cholera toxin subunit B (CTB) fused
with acid alpha glucosidase (GAA)
CTB-GAA (Cholera, Pompe disease)
Tobacco Between 0.13 and 0.21% of TLP CTB-GAA fusion protein
significantly suppressed
immunoglobulin formation against
GAA in Pompe mice
Su et al., 2015a
CTB fused with Mycobacterium
tuberculosis antigens ESAT-6 and
Mtb72F (a fusion polyprotein from two
TB antigens, Mtb32 and Mtb39)
(Cholera, TB)
Tobacco Lettuce Maximum expression was 7.5% of
TSP in mature tobacco leaves for
CTB-ESAT-6
Hemolysis assay with purified
CTB-ESAT6 protein showed partial
hemolysis of red blood cells
confirming the functionality of
ESAT-6
Lakshmi et al., 2013
(Continued)
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TABLE 1 | Continued
Vaccine Antigen (Disease) Expression
system
Maximum expression level Immunological investigation References
Major membrane protein I (mmpI)
from Mycobacterium leprae fused
with LTB (TB)
Tobacco Not reported Not tested Hassan et al., 2013
EspA and Tir/Intimin antigens from
enterohemorrhagic E. coli O157:H7
(hemorrhagic colitis)
Tobacco Up to 1.4% of TSP Upon oral administration of
tobacco plant leaves high IgG and
IgA specific antibodies were
detected in serum and feces of
mice
Karimi et al., 2013
Domain IV of Bacillus anthracis
protective antigen gene [PA(dIV)]
(Anthrax)
Tobacco 5.3% of TSP Antibody titers of >104 were
induced upon intraperitoneal (ip)
and oral immunizations with plant
derived PA(dIV). Mice challenged
with B. anthracis showed 60% and
40% protection upon ip and oral
immunization with adjuvanted
plant PA(dIV)
Gorantala et al., 2011
Anthrax protective antigen (PV)
(Anthrax)
Tobacco 2.5–4% of TSP Intraperitoneal and oral
immunization with plant PA in
murine model indicated high
serum PA specific IgG and IgA
antibody titers. Oral immunization
experiments demonstrated
generation of immunoprotective
response in mice
Gorantala et al., 2014
PROTOZOAN ANTIGENS
Plasmodium falciparum surface
protein 25 (Pfs25) and 28 (Pfs28)
(Malaria)
Chlamydomonas
reinhardtii
0.5 and 0.2% of TSP, respectively Antibodies to algae-produced
Pfs25 were bond to the surface of
in vitro cultured P. falciparum
sexual stage parasites and
exhibited transmission blocking
activity
Gregory et al., 2012
Plasmodium falciparum surface
protein (Pfs25) fused to the β subunit
of the cholera toxin (CtxB) (Malaria)
Chlamydomonas
reinhardtii
0.09% TSP Algae produced CtxB-Pfs25
elicited CtxB-specific serum IgG
antibodies and both CtxB- and
Pfs25-specific secretory IgA
antibodies
Gregory et al., 2013
Toxoplasma gondii surface antigen of
(SAG1), alone and in fusion with heat
shock Protein of Leishmania infantum
(LiHsp83) SAG1, chLiHsp83-SAG1
(Toxoplasmosis)
Tobacco 0.1–0.2µg/g fresh weight Human seropositive samples
reacted with chloroplast-derived
SAG1, oral immunization in mice
elicited significant reduction of the
cyst burden
Albarracín et al., 2015
T. gondii GRA4 antigen
(Toxoplasmosis)
Tobacco 0.2% of total protein Oral immunization with chlGRA4
resulted in a decrease of 59% in
the brain cyst load of mice
compared to control mice.
ChlGRA4 immunization elicited
both mucosal immune responses
Yácono et al., 2012
Sexual stage antigenic surface protein
Pfs48/45 antigen of Plasmodium
(Malaria)
Chlamydomonas
reinhardtii
Not reported Not tested Jones et al., 2013
AUTOANTIGENS
Human proinsulin (A, B, C peptides)
containing three furin cleavage sites
fused with CTB (CTB-PFx3) (Diabetes
type-1)
Tobacco Lettuce 47% of TLP in tobacco 53% of TLP in
lettuce
Oral delivery of unprocessed
proinsulin bioencapsulated in plant
cells or injectable delivery into mice
showed reduction in blood glucose
levels similar to processed
commercial insulin
Boyhan and Daniell, 2011
(Continued)
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TABLE 1 | Continued
Vaccine Antigen (Disease) Expression
system
Maximum expression level Immunological investigation References
Human proinsulin gene fused with
protein A (Diabetes type-1)
Tobacco 0.2% of TSP Not tested Yarbakht et al., 2015
Exendin-4 (EX4) fused with CTB
(Diabetes type-2)
Tobacco 14.3% of TLP Upon oral delivery in mice
CTB-EX4 stimulated insulin
secretion similar to the
intraperitoneal injection of
commercial EX4
Kwon et al., 2013
via pollen or to the environment or food chain vertically as well
as horizontally. Certain aspects of environment safety concerns
can be addressed by opting plastid transformation. In most
plant species, plastids follow maternal inheritance pattern, i.e.,
not transferred through pollen. This is a major advantage of
plastids that should aid in addressing the regulatory concerns
related to genetically modified plants (GMPs) because there
will be no or very negligible outflow of plastid DNA paternally
(Daniell, 2007; Ruf et al., 2007; Svab and Maliga, 2007). In case
of tobacco, there is an extra advantage that it is a non-food non-
feed crop that is not very common as wild. Hence, chances of
crossing transplastomic plants with any wild species are excluded.
Generally, the risk of horizontal gene transfer from plants to
microorganisms, particularly when transformed plants contain
antibiotic resistance genes, is very low and there is no existing
report of such incidence (Obembe et al., 2011). The risk goes
more toward downside by the fact that plants naturally harbor
many bacteria that contain antibiotic-resistant genes (Nielsen
et al., 1998). Hence, it can be argued that horizontal gene transfer
to soil bacteria is very negligible. Considering the advantage
of chloroplast transformation related to transgene containment,
it is very likely that field trials can be allowed in isolated
areas at local level in developing countries after addressing the
containment issues to the local authorities. Permission of field
trials of transplastomic plants may be easier in case of non-
food and/or non-feed crops such as tobacco, because in such
case the risk of human food chain contamination is minimal. If
safety concerns are addressed, field trials are allowed and have
been done previously in various countries for plant/chloroplast
derived recombinant proteins and biopharmaceuticals (Arlen
et al., 2007; Hefferon, 2015).
Plant-based vaccines have the potential to be used for oral
administration. However, a matter of concern is that whether
the consumption of plant-made pharmaceuticals is safe for
administration or not. In general, plants are safe for human
consumption as plants are not host for human pathogens and
many plant species such as lettuce are consumed in normal diet
as raw. However, for consuming transgenic plants, safety needs to
be addressed. There are several reports in which safety of plant-
based pharmaceuticals have been shown in animal models via
oral delivery against different diseases using raw plant material
(for review see Lössl and Waheed, 2011; Chan and Daniell,
2015). However, in addition to product used for treatment, raw
material also contains unwanted antibiotic resistant gene that
raises concerns regarding safety and needs to be addressed in
humans. This problem can be covered by: using selectionmarkers
other than antibiotic resistant genes, excising the antibiotic
resistant genes after selection (Iamtham and Day, 2000) or
purifying the final product. Although purification will add to
the cost, yet it will address an important regulatory concern. In
context of purification of plant-based vaccines, it is pertinent to
mention that these vaccines will require less stringent purification
methods compared to fermenter-based systems.
STABILITY OF
PLANT/CHLOROPLAST-EXPRESSED
PROTEINS
In developing countries, a major limitation can be the
maintenance of cooling chain during storage or when delivering
the vaccines to remote areas. This factor may additionally add
to the costs related to the production of vaccines. Plant-based
vaccines have a potential that these can be stored at room
temperature in the form of dried material for longer period
of time. There are many reports which show that the protein
expressed in plants remained stable at room temperature or
even at elevated temperatures for a longer period of time
when stored as dried plant material. An algal chloroplast-
derived vaccine antigen remained stable for 20 months at
room temperature in lyophilized form and was comparably
immunogenic when tested in comparison with the antigen stored
at 4◦C (Dreesen et al., 2010). In another report, transplastomic
lettuce leaves expressing CTB fused with ESAT-6 (antigen from
Mycobacterium tuberculosis) were lyophilized and stored for 6
months at room temperature (Lakshmi et al., 2013). After 6
months CTB-ESAT6 fusion protein was stable and preserved
proper folding, disulfide bonds and assembly into pentamers.
Lyophilization also increased the antigen concentration per gram
of leaf tissue up to 22-fold. Gregory et al. (2013) demonstrated
that CtxB-Pfs25 accumulated as a soluble, properly folded and
functional protein within algal chloroplasts, and it was stable
in freeze-dried alga cells at ambient temperatures. Kwon et al.
(2013) expressed exendin-4 (EX4) as a cholera toxin B subunit
(CTB) fusion protein. They observed that lyophilization of
leaf material increased therapeutic protein concentration by
12- to 24-fold, extended their shelf life up to 15 months
when stored at room temperature and eliminated microbes
present in fresh leaves. In addition, the pentameric structure,
disulphide bonds, and functionality of CTB-EX4 were well
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preserved in lyophilized materials (Kwon et al., 2013). In a
recent report Su et al. (2015a) showed that plastid-derived
cholera toxin subunit B fused with acid alpha glucosidase (CTB-
GAA) concentration was increased by lyophilization to 30-fold
(up to 190µg per g of freeze-dried leaf material). Same group
(Su et al., 2015b) expressed coagulation factor IX (FIX) fused
with CTB in commercial lettuce. They showed that CTB-FIX
in lyophilized cells was stable with proper folding, disulfide
bonds, and pentamer assembly when stored for approximately
2 years at ambient temperature. All these reports strengthen
the fact that plant/chloroplast-produced biopharmaceuticals can
be stored at room temperature for long periods of time in the
form of lyophilized material. A vaccine may be very effective
in the laboratory; however, its commercial potential can be
limited unless suspension can be stabilized for storage and
distribution. Alternative techniques such as establishment of
a cold chain may cause the potential loss of vaccine stocks
resulting from freezer failure and also adds to the costs when
distributing frozen materials. Lyophilization (freeze-drying) is a
well-established technique used in the pharmaceutical industry
for stabilizing high-cost, labile bioproducts, such as vaccines
(Adams, 2003). Firstly, plant-produced vaccines can be stored
in the form of dried plant material. This will also increase the
antigen concentration. Alternatively, plant-derived vaccines can
be purified and lyophilized for storage at room temperatures and
transported when required. This strategy will help to circumvent
cooling chain in developing countries and thus eliminating the
costs related to storage and transportation under cooling.
WHAT NEXT?
It has been almost 14 years since the expression of first vaccine
candidate antigen against human diseases in chloroplasts of
Nicotiana tabacum (Daniell et al., 2001b). Since then lot of
research has been done on different aspects of expression that has
resulted in improved protocols and a very high expression level
has been achieved in chloroplasts. In 80–90% of cases, tobacco
is used for the chloroplast-based expression and comparatively
very little research has been done on other plant species. For
tobacco, excellent data is available to follow for chloroplast-
based vaccine production. However, despite of all this research,
not a single plant/chloroplast-based vaccine against human
diseases has entered the market and hence humanity has not
been benefited. What is needed but lacking is more industrial
interest. Big pharma companies have already well-established
platforms for the production of pharmaceutical compounds. A
good amount of revenue is already generated from these systems.
To adopt plant-based systems, pharmaceutical companies would
need to invest money and resources to develop their own
platforms. In addition, clinical trials and the ultimate regulatory
approval would also require cost and time. In contrast, newly
established pharma companies or small industries can adapt
more quickly to plant-based systems because opting to new cost-
effective systems will help these industries to compete and earn
more compared to the expenditures. Another possible solution
can be to establish and strengthen the research/academia-
industry linkages. Research groups in collaboration with industry
can develop platforms that could be later taken over by the
industries. Such collaborative projects can be funded by many
organizations that are working for the control of diseases
throughout the world. Since, many cost-effective vaccines are
needed mainly in developing countries, initially platforms can be
established directly in those countries where vaccines are mostly
needed. Small pharmaceutical industries can be collaborated
to run the projects directly in a developing country where
the product is to be utilized. Growing of plants, harvesting,
processing and packaging can be carried out locally that will
be economical due to less labor and land costs as compared to
developed countries. A possible attraction for the pharmaceutical
companies can be an adequate amount of revenue that can
be generated from the production of vaccines and its launch
to previously uncovered areas. This will be especially valid in
those cases where already marketed vaccines such as those
against HPV are very expensive and hence the large market of
developing world remains uncovered. An affordable alternative
solution in such cases can bring a handsome amount of
turnover to the companies. The involvement of local pharma
will be necessary because production can be more cost-
effective if manufactured locally rather than exporting from a
distant industrially developed country. In this way costs related
to transportation and maintenance of cooling chain will be
circumvented. Another advantage of this strategy will be the
strengthening of local small pharmaceutical industries that will
also help in the economic uplift of low and middle income
countries. To achieve this, technology can be established in
the developed countries in the laboratories/industries. Thus,
a stable genetic resource in the form of seeds can be
maintained in developed countries where more funding is
available for research. The technology can be initially patented
where developed. Later, local pharmaceutical companies, local
governments and/or humanitarian organizations can be engaged
to set up the industrial scale production platforms. Involvement
of local governments and organizations such as world health
organization (WHO) can serve to utilize already existing setups
of vaccine storage, transportation and administration. However,
a local patent may be needed if license is already not obtained
in developing country, for which some variations in the
existing established protocols of expression may be needed. To
accomplish these goals, already established tobacco prototypes
may be taken and advanced to the industrial level. Two main
advantages of adopting tobacco chloroplast transformation: non-
edible nature of tobacco thus avoiding food chain contamination
and lack of transgene transmission due to maternal inheritance
of chloroplasts may facilitate to address biosafety concerns in
the target developing country and thus making large scale
production in the fields possible. Established protocols, high
level of expression and high biomass are additional reasons that
make this species ideal for vaccine production at large scale.
Other possible alternative plant species may be lettuce due to
its high biomass and broad leaf. Taking lettuce for industrial
level production will be more realistic in achieving the successful
patent due to less number of existing protocols.
Efficacy of plant-based vaccines has been very well shown in
animal models. Large number of reports exists that show many
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potential vaccine candidates and their high immunogenicity
in different animal models (Rybicki, 2014). Now the need is
to investigate immunogenicity and safety of some prominent
vaccine candidates in humans. For this purpose, relevant medical
groups and industries can be involved in the design of research
projects so that resources and funding may become available for
human clinical trials.
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